AMP-101 not checked

Amplo Biotechnology

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Route of Administration: intravenous infusion Unit Dose Strength: 5.02 x10\^13 Vg/ml in a volume of 1 mL/vial”In the company’s words, NCT07830563 on ClinicalTrials.gov
Tested for
Congenital Myasthenia Syndrome
Main trialPhase 1
“This study is evaluating the safety and potential effects of AMP-101 in people with DOK7 Congenital Myasthenia Syndrome (CMS). Participants will receive a single dose of the study treatment and will be monitored to assess their health and response to treatment. Approximately 4 participants are expected to take part in the study.”In the company’s words, NCT07830563 on ClinicalTrials.gov

Other drugs for Congenital Myasthenia Syndrome

All 2 drugs for Congenital Myasthenia Syndrome

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 1 Oct 2028 Evaluating the Safety and Effects of AMP-101 in People With DOK7 Congenital Myasthenia Syndrome
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow AMP-101

Following is part of Solo: you see every change to AMP-101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in